For individuals hospitalized with COVID-19, continuing treatment with dexamethasone at discharge is not associated with a reduction in 14-day all-cause readmission or mortality, according to a study published online March 8 in JAMA Network Open.
Continued dexamethasone at discharge not tied to better COVID-19 outcomes
For individuals hospitalized with COVID-19, continuing treatment with dexamethasone at discharge is not associated with a reduction in 14-day all-cause readmission or mortality, according to a study published online March 8 in JAMA Network Open.